Sol-Gel Technologies Ltd. (SLGL)
SLGL trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$68.30
-5.66% on the day
Market cap
$223.6M
Micro cap
Revenue · 2025
$19.4M
+68.0% on 2024
Net income · 2025
-$6.1M
-31.6% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | SLGL on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Israel |
| IPO year | 2018 |
| SEC CIK | 0001684693 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | L3 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $19.4M |
| Net income | -$6.1M |
| Operating income | -$7.5M |
| Net margin | -31.6% |
| Operating margin | -38.9% |
| Revenue growth | +68.0% |
| Cash | $11.0M |
| Total assets | $29.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 11.5× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-03-24 |
| Latest annual report | 20-F | 2026-03-19 |
| Latest quarterly / interim | 6-K | 2026-10-06 |
Source: SEC EDGAR submissions feed, 328 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| LRMR | Larimar Therapeutics Inc. | $2.16 | -14.63% | $224.4M |
| NATR | Nature's Sunshine Products Inc. | $12.76 | +0.39% | $224.5M |
| KROS | Keros Therapeutics Inc. | $11.23 | -3.27% | $222.7M |
| SIGA | SIGA Technologies Inc. | $3.08 | -2.53% | $221.3M |
| PYXS | Pyxis Oncology Inc. | $1.85 | -7.96% | $221.2M |
| ZNTL | Zentalis Pharmaceuticals Inc. | $2.40 | -4.76% | $227.2M |
| GLSI | Greenwich LifeSciences Inc. | $15.50 | -12.77% | $227.5M |
| IFRX | InflaRx N.V. | $1.55 | -2.52% | $228.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier